Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$651.00M+27.96%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Norman D. Schwartz
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 7,450
- Beta
- 1.07
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.65
Financials
Revenue
$651.00M+28.0%Net Income
$371.40M+1917.9%EBITDA
$542.10M+711.4%Free Cash Flow
$66.70M+449.0%EPS (diluted)
$13.85+2133.9%Shares Outstanding (diluted)
26.81M-9.6%Operating Expenses
$273.20MCash & Debt
$1.62BReturn of Capital
$47.20MRevenue by Segment (annual)
$2.58BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.58B | $759.90M | $27.87 |
| 2024 | $2.57B | $-1.84B | $-65.36 |
| 2023 | $2.67B | $-637.32M | $-21.82 |
| 2022 | $2.80B | $-3.63B | $-121.79 |
| 2021 | $2.92B | $4.25B | $142.61 |
| 2020 | $2.55B | $3.81B | $127.86 |
| 2019 | $2.31B | $1.76B | $58.93 |
| 2018 | $2.29B | $361.00M | $12.10 |
| 2017 | $2.16B | $114.74M | $4.12 |
| 2016 | $2.07B | $28.13M | $0.88 |
| 2015 | $2.02B | $113.09M | $3.74 |
| 2014 | $2.18B | $88.84M | $3.08 |
| 2013 | $2.13B | $77.79M | $2.72 |
| 2012 | $2.07B | $169.23M | $5.85 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BIO's reported EPS growth of 12.8% a year over 13 years.
- EPS in 5 years
- $50.90
- Implied price
- $559.91
- Return from $369.14
- 8.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $278.38 — -24.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 7 | 9 | 11 | 13 | 15 |
|---|---|---|---|---|---|
| 2.8% | -9.5% | -4.8% | -0.9% | 2.4% | 5.4% |
| 7.8% | -5.1% | -0.2% | 3.9% | 7.4% | 10.5% |
| 12.8% | -0.7% | 4.4% | 8.7% | 12.4% | 15.6% |
| 17.8% | 3.7% | 9.0% | 13.5% | 17.4% | 20.8% |
| 22.8% | 8.1% | 13.7% | 18.3% | 22.3% | 25.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (19)
- Newsglobenewswire.com·7d ago·Neutral
BIO-key Partners with Al Majlis Group to Expand Identity Security Across Arabian Gulf BIO-key (BKYI) Partners with Al Majlis Group, Founded by His Excellency Dherar Belhoul Al Falasi, to Expand Identity Security Across Arabian Gulf Region.
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
… Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for Leadership Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets. com's offering. The global magnetic beads market was valued at an estimated US$3. 3 billion in 2025 and is projected to reach US$7.
View source ↗ - Newsmarketbeat.com·10d ago·Neutral
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions.
View source ↗ - Newsseekingalpha.com·11d ago·Positive
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newszacks.com·12d ago·Negative
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
BIO-key Receives FIDO Alliance Full Certification for Passkey:YOU™ Authentication, Unlocking New Markets Including Agentic AI Authenticated Controls HOLMDEL, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and tokenless Identity-Bound Biometrics™ (IBB) authentication, today announced that its Passkey:YOU™ authenticator has received Full…
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Bio-Rad: Favorable Read-Across From Investor Event Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives NEW YORK and TOKYO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
View source ↗ - 4chan /biz/biz·32d ago·Positive
because you ure supposed to buy BIO and aster to 1000x phag its all about biotech and most powerful dex (yes hype is dead)
View source ↗ - News (RSS)hellenicshipping·39d ago·Positive
BIO-UV Upgrades Bio-Sea Control Panel With Traffic Light System BIO-UV Group has upgraded the control system for its BIO-SEA ballast water management system (BWMS), introducing new features to help crews identify changes in treatment capacity and filter performance when operating in challenging water conditions. The new BIO-SEA control panel, officially unveiled for the first time at the SMM 2026 exhibition in Hamburg, features a ...
View source ↗ - 4chan /biz/biz·45d ago·Neutral
link is dead, RED stone is the new link, it gained the biggest momentum surpasing any btc dominance corrections. Same will do ENA and BIO, fastest growing. if you dont own winners, u gon lose /thread
View source ↗ - Newszacks.com·45d ago·Positive
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
View source ↗ - Newszacks.com·46d ago·Positive
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building? BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
BIO-key's Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally; Call Tomorrow at 10am ET BIO-key's (BKYI)Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally.
View source ↗ - Newsglobenewswire.com·54d ago·Positive
BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced second quarter financial results and provided a business update.
View source ↗ - News (RSS)seekingalpha·55d ago·Neutral
BIO-key International enters $2.5M warrant inducement transaction
View source ↗ - Newszacks.com·56d ago·Neutral
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
Portuguese National Security Agency Selects BIO-key and Visualforma to Strengthen Identity Security Portuguese national security agency selects BIO-key (BKYI) and Visualforma to strengthen identity security with advanced IAM and biometric authentication.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $2.23 per share
Typical surprise +1.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$2.62 vs $1.75beat
- Thu, Apr 30$1.89 vs $1.97miss
- Thu, Feb 12$2.51 vs $2.57miss
- Wed, Oct 29$2.26 vs $2.30miss
- Thu, Jul 31$2.61 vs $1.93beat
- Thu, May 1$2.54 vs $1.73beat
Estimates and results for BIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIO officers and directors.
- Bought
- —
- Sold
- $350k
0 trades
2 trades
- Engelhardt Eva Anettesold
- Barry Jamessold
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (13d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Lois Frankelhouse · FL22 · disclosed Oct 10, 2023 (32d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL22 · disclosed Jul 28, 2023 (30d later)Buy$1,001 - $15,000
- Lois Frankelhouse · FL22 · disclosed Jul 28, 2023 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Dec 29, 2022 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2022 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 10, 2022 (21d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 7, 2022 (20d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 6, 2022 (23d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Apr 8, 2022 (9d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (19d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (19d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (18d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jul 23, 2021 (116d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Feb 10, 2021 (36d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Dec 8, 2020 (67d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.